Company intelligence / Profile preview
Lexeo Therapeutics
New York City, New York, United Stateslexeotx.com ↗
- Ownership
- Public · LXEO
- Development stage
- Phase 1
01
Overview
Positive interim Phase 1/2 data for LX2006 in Friedreich's ataxia cardiomyopathy showing improvement in left ventricular mass index (LVMI) and frataxin expression, supporting advancement to registrational study. Also has ongoing Phase 1/2 trial for LX1001 in APOE4-associated Alzheimer's disease with completed enrollment.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- AAV-mediated gene therapy
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
Weill Cornell MedicineUniversity of California San Diego
04
Financials
- Market cap
- $238.5M
- Total revenue
- $0
- Enterprise value
- $33.6M
Beyond the preview
Go deeper on Lexeo Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lexeo Therapeutics.